NetwoRx Bio

Company Overview

Snapshot

Founded in May 2024 by Ori Choshen, NetwoRx Bio operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing its core technology for immunotherapy.

Business overview

NetwoRx Bio is a Health Tech & Life Sciences company that leverages cutting-edge computational biology and AI-driven analytics to decode complex communication networks within the tumor microenvironment. The company generates a proprietary NetwoRx Score, a patient-specific metric that identifies actionable molecular interactions to predict response to various immunotherapeutic treatments. This technology aims to optimize clinical trial design by matching immunotherapeutic drugs to the right indications and patient populations, and to deliver precision medicine by identifying patients most likely to benefit from specific treatments. NetwoRx Bio operates in the pharmaceuticals and biotechnology sectors, serving the healthcare and life sciences industries across Europe, Americas, and Asia.

Company Intelligence Q&A

What is NetwoRx Bio's primary focus?

NetwoRx Bio focuses on revolutionizing immunotherapy trials by applying AI-driven insights to drug-indication-biomarker analysis, aiming to enhance treatment response and overcome resistance.

When was NetwoRx Bio founded?

NetwoRx Bio was founded in May 2024.

Who is a co-founder of NetwoRx Bio?

Ori Choshen is a co-founder and CEO of NetwoRx Bio.

What technology does NetwoRx Bio utilize?

NetwoRx Bio harnesses cutting-edge computational biology and advanced AI-driven analytics to understand the tumor microenvironment and generate its proprietary NetwoRx Score.

What is the NetwoRx Score?

The NetwoRx Score is a patient-specific metric generated by NetwoRx Bio's AI-driven analytics, designed to identify actionable molecular interactions and predict response to immune checkpoint inhibitors, monoclonal antibodies, and small molecule immune modulators.